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Abstract 
BACKGROUND: In recent years’ medical management with misoprostol is an effective alternative to surgical 
evacuation. But there is a dearth of evidence to reveal the effectiveness of the different routes of misoprostol and 
satisfaction rate among the patients treated with these routes.  
AIM: This study was conducted to compare the effectiveness and patient’s satisfaction rate of vaginal versus oral 
misoprostol. 
METHODS: It was a prospective non-interventional study. One hundred women of having missed abortion 
confirmed by ultrasonography examination were enrolled in the trial. Fifty-eight subjects were administered 200 
mcg of oral and 42 subjects received 200 mcg of vaginal misoprostol every four hours up to four doses. If 
complete expulsion did not occur 12 hours after the last dose, the surgical evacuation was done. 
RESULTS: There was no significant statistical difference between the effectiveness of treatment with vaginal 
(78.57%) and oral misoprostol (79.31%) (p = 0.928). The difference between Patients’ satisfaction at the time of 
discharge for the vaginal group (64.29%) and oral group (65.52%) was not statistically significant (P = 0.991). 
There was an increase in patients’ satisfaction for both groups at the follow-up session, but still, the difference 
was not significant (P = 0.897). 
CONCLUSION: This study confirms that there is no statistical difference between the effectiveness and patient 
satisfaction of oral and vaginal misoprostol in the treatment of missed abortion. 
 
 
 
 
 
 
 
 
Introduction 
 
In the past, treatment for miscarriage before 
14 weeks consisted of aggressive surgery [1].  But 
surgery is associated with many complications, such 
as postoperative infection [2]. However, in recent 
years, medical management has been introduced 
which is effective, safe, and acceptable
 
[3]. Till now, 
so many different regimens have been tried and used, 
more or less successfully and it is one of the most 
confusing aspects of medical treatment of abortion. 
More than one regimen may be effective at a 
particular stage of pregnancy [4]. Misoprostol is an 
effective agent commonly used in the treatment of 
miscarriages especially missed miscarriage, but 
optimal dose and route of administration of 
misoprostol have not been determined by randomised 
trials [5]. Even the World Health Organization has not 
recommended a standard regimen for administration 
of misoprostol in the treatment of missed miscarriage 
[6]. 
A study was performed to find out the effect of 
misoprostol route on its pharmacokinetic profile [7]. 
There was the best absorption of misoprostol 
following vaginal administration. Small drug doses 
administered vaginally were capable of inducing 
contraction of uterus slowly and maintaining it for 
induction of labour. Due to the higher peak in oral 
administration, the side effects were more compared 
to that of the vaginal route [7]. Although the studies 
performed there is no agreement among experts in 
the superiority of the effectiveness of oral misoprostol 
over vaginal misoprostol and vice versa. Some 
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studies revealed that vaginal misoprostol is more 
effective than oral one in the expulsion of uterine 
content [8]. However, some other studies showed that 
there is not any significant difference between oral 
misoprostol and vaginal form of that [9]. Another 
important issue that should be considered in the 
treatment of missed abortion is the acceptability and 
satisfaction of the patient with the administered 
treatment. Because patients of having missed 
abortion experience grief, anxiety and depression, the 
method of treatment may affect their emotional state 
[10]. Some trials have concluded that women have 
higher satisfaction with oral misoprostol
 
[11] while 
some other findings were against the superiority of 
oral misoprostol over the vaginal form of that 
considering the patient's satisfaction [9].  
Since there is no fixed standard regimen for 
the treatment of missed abortion and because the way 
of treatment can affect the patients emotionally, 
further studies can be helpful. So in this study, we 
investigated the effectiveness of 800 mcg oral 
misoprostol versus vaginal misoprostol in a tertiary 
care hospital in India. Also, patients’ satisfaction 
treated with vaginal versus oral misoprostol was 
compared at the time of discharge and in a follow-up 
session. 
 
 
Material and Methods 
 
Study Design 
The study was a non-interventional 
prospective trial conducted in Sapthagiri hospital, 
Bangalore. Women who were eligible for the study 
were thoroughly counselled, and informed consent 
was taken orally. 
 
Inclusion and exclusion criteria 
Patients were recruited for the study based on 
the following inclusion criteria: 
1. Females of age group 18 to 45 years, 2. 
Women with a gestational age of < 13 weeks of 
gestation from LMP, 3. Diagnosis of missed abortion 
by USG, 4. Mild vaginal bleeding or spotting or no 
bleeding and spotting at all, 5. Close cervix on pelvic 
examination, 6. Haemoglobin ≥ 9 gm/dl, 7. No history 
of asthma, liver disease on known allergy to 
misoprostol 
 Woman with any degree of cervical dilation, 
excessive uterine bleeding, twin gestation sac, molar 
pregnancy, BP ≥ 160/ 90 mmHg, signs and symptoms 
of infection, long-term corticosteroid therapy, and 
patients with high risk of uterine rupture and women 
who refused compliance with follow up schedule are 
excluded from the trial.  
During a one-year study from September 
2016 to September 2017, we enrolled 100 women, 
each with a documented missed abortion < 13 weeks 
of gestation through ultrasound examination. The 
subjects were administered mifepristone on day one 
followed by oral or vaginal misoprostol on day 3. Out 
of 100, 42 patients received 200 mcg of vaginal 
misoprostol, and 58 subjects received 200 mcg of oral 
misoprostol every four hours up to four doses. The 
patients were examined for complete expulsion of 
uterine content. If complete expulsion did not occur 12 
hours after the last dose, the surgical evacuation was 
done. 
 
Study Procedure 
All patients were monitored for vaginal 
bleeding and expulsion of uterine content. In case of 
any expulsion, the POCs were examined by the 
gynaecologists. Also, a bimanual pelvic examination 
was performed to determine any retained gestational 
material. If complete abortion occurred before the 
completion of all doses, the next doses were not 
given. 
Clinical outcomes had been considered 
before the initiation of the trial as: 
- The effectiveness of trail had been defined 
as the expulsion of uterine content completely without 
the need for surgery. 
- Failure was defined as the need for surgery 
for completing the course of treatment. 
Clinical outcomes were recorded 12 hours 
after the last dose of misoprostol. The surgical 
evacuation was done in case of severe pain, infection, 
heavy vaginal bleeding or failure of complete 
expulsion of POCs after administration of the last 
dose of misoprostol. 
Subjects were observed for 12 hours after 
complete abortion and then discharged. All women 
were then asked to return to hospital 14 days after 
discharge for examination with USG to make sure that 
there was no retention of any conception product in 
the uterine, also for assessing their satisfaction. The 
subjects were asked to fill a multiple- choice 
questionnaire by themselves at two-time points: one 
at the time of discharge from hospital and one at 
follow-up session 14 days after their discharge from 
the hospital. 
 
Statistical analysis 
The data were recorded in mean ± SD. 
Statistical significance was determined by Chi-square 
test for complete evacuation and patient satisfaction. 
P < 0.05 was considered statistically significant. The 
SPSS 16.0 statistical package was used for analysing 
the data.  
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Results 
 
As mentioned in Table 1, baseline 
characteristics of both groups in terms of age, parity 
and period of gestation were comparable. 
Table 1: Characteristics of the patients 
Characteristics Vaginal group 
(n = 42) 
Oral group 
(n = 58) 
Age (years)   
18-27 14 (33.33) 20 (34.48) 
28-37  22 (52.38) 30 (51.72) 
38-45 6 (14.28) 8 (13.79) 
Mean ± SD 32.41 ± 3.52 34.61 ± 3.14 
Parity   
1 8 (19.04) 11 (18.96) 
2 10 (23.80) 14 (24.13) 
3 20 (47.61) 25 (43.10) 
4 
mean± SD 
4 (9.52) 
2.47 ± 0.90 
8 (13.79) 
2.51 ± 0.95 
Gestation duration (weeks)   
5-6 
7-8 
9-10 
11-12 
Mean ± SD 
1 (2.38) 
9 (21.43) 
22 (52.38) 
10 (23.81) 
9.35 ± 1.34 
0 (0) 
23 (39.66) 
17 (29.31) 
18 (31.03) 
9.34 ± 1.52 
Values are given a number or number (percentage) unless otherwise indicated. 
 
There was no significant difference between 
oral and vaginal route (Table 2) in success of 
treatment (2 = 0.008; P = 0.928; df = 1). 
Table 2: Effectiveness of vaginal and oral misoprostol in the 
treatment of missed abortion 
 Success Failure 2 
(p-value) 
Vaginal 33 (78.57) 9 (79.31) 0.008 
Oral  46 (21.43) 12 (20.69) (P= 0.928) 
Values are given a number or number (percentage) unless otherwise indicated. 
 
There was no significant difference of 
patient’s satisfaction between oral and vaginal 
misoprostol (Table 3) at time of discharge (2 = 
0.0162; P = 0.991; df = 2). 
Table 3: Patients satisfaction at the time of discharge 
 Satisfied Unsatisfied Don’t know 
(P value) 
2 
 
Vaginal  27 (64.29) 6 (14.29) 9 (21.43) 0.016 
(0.991) Oral 38 (65.52) 8 (13.79) 12 (20.69) 
Values are given a number or number (percentage) unless otherwise indicated. 
 
There was no significant difference of 
patient’s satisfaction between oral and vaginal 
misoprostol (Table 4) at follow-up session (2 = 4.822; 
P = 0.897; df = 2). 
Table 4: Patient satisfaction at a follow-up session 
 Satisfied Unsatisfied Don’t know 2 
(P value) 
Vaginal  31 (73.81) 2 (4.76) 9 (21.43) 
Oral 49 (84.48) 5 (8.62) 4.82 (0.897) 
9 (6.90) 
Values are given a number or number (percentage) unless otherwise indicated. 
 
The complete abortion rate in the vaginal 
group was 78.57%, while it was 79.31% in the oral 
group. The abortion rate was higher in the oral group. 
However, the difference was not statistically 
significant (P = 0.928) 
The questionnaires filled by the patients at 
two times of discharge showed 64.29% patients’ 
satisfaction for vaginal treatment and 65.52% for oral 
treatment. But the difference was not significant 
statistically (P = 0.991). Patients’ satisfaction for both 
groups increased at follow-up session and at this time 
point the result of patients’ satisfaction of oral 
treatment (84.48%) was higher than that of the vaginal 
group (73.81%), but the difference was not statistically 
significant (P = 0.897). 
 
 
Discussion 
 
Misoprostol is an effective agent commonly 
used in the treatment of miscarriages but in spite of 
the studies that have been conducted the optimal 
dose and route of administration of misoprostol have 
not been determined yet [5].
 
Studies showed that the 
degree of absorption of misoprostol and its effect on 
uterine contractility after vaginal misoprostol was more 
long-lasting and more continuously increasing uterine 
contractility comparing to the time when oral 
misoprostol was administered After vaginal 
administration [3]. The difference between AUC 
values of orally and vaginally administered 
misoprostol is likely due to pre-systemic 
gastrointestinal or hepatic metabolism of oral 
misoprostol that will not happen in vaginal route [12]. 
So higher efficacy of vaginal misoprostol is expected 
due to the greater bioavailability of this route. 
However, in spite of the logical explanation 
that vaginal misoprostol may be more effective than 
oral misoprostol due to their pharmacokinetic 
differences, in our study, there was no statistically 
significant difference in terms of response to treatment 
between oral misoprostol and vaginal misoprostol (P = 
0.928). Although there are some studies that their 
results are contrary to our findings [1], [8], [13], [14], 
[15], [16], [17], there are some studies that support 
our findings [9], [18]. 
It was stated that age of gestation could 
influence the effectiveness of oral and vaginal 
misoprostol [27], but in our study, the subjects of two 
groups were very similar in the gestation duration 
(mean ± SD = 9.35 ± 1.34 for the vaginal group and 
mean ± SD = 9.34 ± 1.52 for the oral group).  
Patient satisfaction is an important factor to 
be considered in the treatment of missed abortion 
because except the physical pain that these patients 
have, they are emotionally involved because of the 
loss of their child. They also suffer grief and 
depression [9].
 
Our study does not show a significant 
difference between patients’ satisfaction of vaginal 
group and the oral group at the time of discharge (p = 
0.991). Patients’ satisfaction result at the second time 
point has increased for both groups (73.8% for the 
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vaginal group and 84.48% for the oral group). But still, 
the difference between the satisfaction of subjects of 
both groups is not statistically significant (P = 0.897).  
From the results that we have obtained, we 
can infer that the emotional status of the patients in 
both groups may affect their response while 
completing the questionnaire at the time of discharge. 
It can be claimed so because the patient’s satisfaction 
in both groups has increased after 14 days which is a 
good time for coming out of their grief. It has been 
stated that due to less privacy of vaginal misoprostol, 
patient show less satisfaction towards this route of 
administration [14] but our study is not in line with this 
finding because both groups of vaginal and oral 
misoprostol showed similar satisfaction towards their 
treatment. This similarity in the satisfaction of the 
subjects can be justified by considering the 
effectiveness of the treatment by these routes. As the 
difference in the effectiveness of both vaginal and oral 
misoprostol was not statistically significant, we can 
conclude that the success of the treatment is one 
important factor affecting patient satisfaction. 
Therefore, it can be concluded that there is no 
difference between the vaginal and oral route of 
administration of misoprostol in the success of the 
treatment and patient satisfaction when used in the 
treatment of missed abortion. 
The small sample size was one of the 
limitations of this study. Also, this study was not a 
controlled one. Further double-blind controlled studies 
with larger sample size are needed to elucidate the 
optimal route of misoprostol and patient satisfaction. 
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